Abstract
Cardiovascular disease (CVD) is the leading cause of mortality worldwide with an estimated 17.3 million deaths from CVD in 2008. Its prevalence clearly demonstrates the need for an intense focus on developing and improving tools used in the diagnosis and treatment of CVD.
One approach where significant headway has been made is through the use of biomarkers. Myriad RBM’s biomarker panels are referenced in nearly 50 publications demonstrating the utility of the multiplex immunoassay approach across a range of studies involving all stages of CVD from diagnosis to prognosis and treatment evaluation.
